Healio

FLOW: Semaglutide cuts kidney, cardiovascular, death risks regardless of SGLT2 use

Please provide your email address to receive an email when new articles are posted on . Semaglutide benefits were observed for adults with type 2 diabetes and chronic kidney disease whether or not ...
Healio

Kidney benefits with semaglutide in FLOW trial consistent regardless of baseline BMI

Please provide your email address to receive an email when new articles are posted on . Semaglutide lowered risk for kidney outcomes consistently across BMI subgroups in the FLOW trial. Body weight ...
Monthly Prescribing Reference

FLOW Trial: Semaglutide Reduces Risk of Kidney Disease Progression

Findings showed treatment with semaglutide 1mg reduced the risk of kidney-disease progression as well as cardiovascular and kidney death by 24% compared with placebo. Treatment with semaglutide ...
Medscape

FLOW: GLP-1 Kidney Benefits Seen With or Without SGLT2 Inhibitors

New data from the landmark FLOW trial, which linked the glucagon peptide 1 (GLP-1) receptor agonist semaglutide with significant kidney outcomes in patients with type 2 diabetes (T2D) and chronic ...
Nasdaq

Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis

Bagsværd, Denmark, 10 October 2023 – Novo Nordisk today announced the decision to stop the kidney outcomes trial FLOW (Effect of semaglutide versus placebo on the progression of renal impairment in ...
Nasdaq

Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the ...

Bagsværd, Denmark, 5 March 2024 – Novo Nordisk today announced the headline results from the kidney outcomes trial FLOW. The announcement today follows the decision to stop the trial early due to ...